In agreement with these findings, a recent study investigating the impact of the PI3Kγ/δ inhibitor TG100-115 on CRC, showed enhanced expression of IL-1β and CXCL10, as well as reduced IL-10 and TGF-β in tumours from TG100-115 treated mice (Lee et al., 2020). This evidence concerns the gene IL10 and neoplasm.